Abstract
Background: Surgery is a known risk factor for hospital-acquired venous thromboembolism (HA-VTE) in children. Objectives: To assess whether the odds of HA-VTE differs across six anatomic sites of noncardiac surgery and to identify risk factors for HA-VTE in these children. Methods: This was a multicenter, case–control study. Anatomic sites of surgery and risk factors for HA-VTE were collected on hospitalized pediatric patients who had undergone a single noncardiac surgery and developed HA-VTE (cases), and those who did not develop HA-VTE (controls), via the Children's Hospital-Acquired Thrombosis (CHAT) Registry. Logistic regression estimated the odds ratio (OR) and 95% confidence intervals (CIs) between six anatomic sites of surgery and 16 putative HA-VTE risk factors. Variables with a p value of 0.10 or less in unadjusted analyses were included in adjusted models for further evaluation. The final model used backward selection, with a significance level of 0.05. Results: From January 2012 to March 2020, 163 cases (median age, 5.7 years; interquartile range [IQR], 0.3–14.2) and 208 controls (median age of 7.5 years; IQR, 3.7–12.9) met our criteria. There was no statistically significant increased odds of VTE among the types of noncardiac surgery. In the final adjusted model, central venous catheter (CVC; OR, 14.69; 95% CI, 7.06–30.55), intensive care unit (ICU) stay (OR, 5.31; 95% CI, 2.53–11.16), and hospitalization in the month preceding surgery (OR, 2.75; 95% CI, 1.24–6.13) were each independently significant risk factors for HA-VTE. Conclusion: In children undergoing noncardiac surgery, placement of CVCs, admission/transfer to the ICU, or hospitalization in the month prior to surgery were positively associated with HA-VTE.
Original language | English (US) |
---|---|
Article number | e12810 |
Journal | Research and Practice in Thrombosis and Haemostasis |
Volume | 6 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2022 |
Funding
E. Amankwah is a consultant for the Data Safety Monitoring Board for Pfizer and Bristol Myers Squibb. E. V. S. Faustino receives grant funding from the National Institutes of Health, American Heart Association, and Grifols Shared Services of North America; and receives an honorarium as medical advisory board member for Boehringer‐Ingelheim. There are no other conflicts of interest disclosed for the authors E. Stephens, A. H. Nguyen, J. Jaffray, B. Branchford, E. Amankwah, N. A. Goldenberg, N. A. Zakai, A. Stillings, E. Krava, G. Young, and J. H. Fargo. The authors would like to recognize the efforts of the clinical research coordinators at the CHAT Consortium sites that contributed to this study. This work was supported by the National Institutes of Health from the National Center for Advancing Translational Science (grant #UL1TR001855) to Julie Jaffray, and the Children's Hospital Saban Research mentored career development award to Julie Jaffray. Funding sources did not have a role in study design, data analysis, writing, or submission of the manuscript.
Keywords
- Hospitals
- Pediatric
- Surgery
- Thrombosis
- Venous thromboembolism
ASJC Scopus subject areas
- Hematology